sepsis
Conditions
Interventions
experimental group:PMB 75mg q12h ivgtt
control group:PMB 50mg q12h ivgtt
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Aged >= 18 and <=75 years; (2) Patients with sepsis caused by CRO infection (Sepsis 3.0 standard), including ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), mediastinal infection, abdominal cavity/biliary tract infection, bloodstream infection, cranial Internal infection, surgical area infection or skin and soft tissue infection, etc.; (3) There is microbiological evidence and drug sensitivity results; (4) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients who have started polymyxin B treatment before enrollment; (2) Patients who cannot obtain informed consent; (3) Patients who participate in other exploratory clinical studies at the same time; (4) Patients who are allergic to research antibiotics; (5) In the terminal stage of the disease, the expected survival is less than 3 months; (6) Pregnant women or patients who need to breastfeed; (7) Those who cannot receive active and comprehensive treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 14-day improvement rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 14-day mortality;28-day mortality;AUC 24 hours and 72 hours after polymyxin administration;Clinical cure;Normal body temperature (below 37.5 degrees C, at least 3 days);Mechanical ventilation time;ICU hospital stay;Total length of stay;Bacteria removal rate;Superinfection;Diarrhea;Compliance rate of blood drug concentration level;Incidence of acute kidney injury; | — |
Countries
China
Contacts
Public ContactTongwen Sun
The The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed